Daiichi Sankyo exon-skips into ultra-orphan ring with DMD alliance

Perhaps encouraged by strong global investor and clinician interest in companies developing new drugs for very rare orphan diseases, Daiichi Sankyo has unveiled plans for a new Japanese joint venture specializing in antisense oligonucleotides for the treatment of Duchenne muscular dystrophy (DMD).